Saturn V Capital Management LP
About Saturn V Capital Management LP’s 13F portfolio
Saturn V Capital Management LP is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , Saturn V Capital Management LP reported $697.5M across 23 US-listed positions (). Its largest position is AMYLYX PHARMACEUTICALS INC (AMLX) at 12% of the reported book, and its ten biggest holdings make up 76% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.
| # | Stock | Price | % of portfolio | Shares | Value |
|---|---|---|---|---|---|
| 1 | NASDAQ: AMLX AMYLYX PHARMACEUTICALS INC | $26.20 −1.58% | 12% | 4.6M | $83.0M |
| 2 | NASDAQ: ALMS ALUMIS INC | $4.33 −1.48% | 12% | 2.9M | $82.0M |
| 3 | NASDAQ: ABVX ABIVAX SA | $80.65 −3.79% | 9.9% | 519K | $69.1M |
| 4 | NASDAQ: PCVX VAXCYTE INC | $58.36 −0.27% | 7.1% | 853K | $49.6M |
| 5 | NASDAQ: IMMX IMMIX BIOPHARMA INC | $7.04 −0.98% | 6.9% | 4.7M | $48.0M |
| 6 | NASDAQ: PHVS PHARVARIS N V | $31.66 +0.35% | 6.5% | 1.3M | $45.4M |
| 7 | NASDAQ: JAZZ JAZZ PHARMACEUTICALS PLC | $236.45 −4.57% | 5.6% | 161K | $38.8M |
| 8 | NASDAQ: CELC CELCUITY INC | $56.31 +1.28% | 5.6% | 370K | $38.7M |
| 9 | NASDAQ: IRON DISC MEDICINE INC | $76.11 −2.40% | 5.5% | 525K | $38.4M |
| 10 | NASDAQ: CADL CANDEL THERAPEUTICS INC | $5.13 −3.57% | 4.9% | 3.3M | $34.0M |
| 11 | NASDAQ: XFOR X4 PHARMACEUTICALS INC | $2.96 −0.67% | 4.7% | 7.0M | $32.6M |
| 12 | NASDAQ: MNPR MONOPAR THERAPEUTICS INC | $70.29 −0.65% | 4.1% | 312K | $28.9M |
| 13 | NASDAQ: DYN DYNE THERAPEUTICS INC | $16.03 +1.01% | 3.4% | 1.1M | $23.5M |
| 14 | NASDAQ: TRVI TREVI THERAPEUTICS INC | $13.72 +1.55% | 2.8% | 1.1M | $19.6M |
| 15 | NASDAQ: ZURA ZURA BIO LTD | $0.95 −1.32% | 1.8% | 2.1M | $12.4M |
| 16 | NASDAQ: SGMT SAGIMET BIOSCIENCES INC | $9.62 −4.85% | 1.6% | 1.5M | $11.4M |
| 17 | NASDAQ: OCS OCULIS HOLDING AG | $7.44 +0.68% | 1.4% | 685K | $9.5M |
| 18 | NASDAQ: IKT INHIBIKASE THERAPEUTICS INC | $1.30 −5.80% | 1.1% | 3.9M | $7.9M |
| 19 | NASDAQ: VIR VIR BIOTECHNOLOGY INC | $8.87 −3.06% | 1.1% | 771K | $7.9M |
| 20 | NASDAQ: IVVD INVIVYD INC | $0.45 −5.23% | 1.0% | 8.4M | $7.3M |
| 21 | NYSE: ANRO ALTO NEUROSCIENCE INC | $26.51 +2.32% | 0.7% | 183K | $4.8M |
| 22 | NASDAQ: MSLE SATELLOS BIOSCIENCE INC | — — | 0.4% | 350K | $2.7M |
| 23 | NASDAQ: OVID OVID THERAPEUTICS INC | $2.34 +3.54% | 0.3% | 663K | $1.8M |
Showing the 23 largest positions reported in this 13F.
- Healthcare100%
- AddedAMLXAMYLYX PHARMACEUTICALS INC+6.3%$83.0M
- AddedPCVXVAXCYTE INC+3.4%$49.6M
- AddedIMMXIMMIX BIOPHARMA INC+26.1%$48.0M
- AddedPHVSPHARVARIS N V+9.4%$45.4M
- AddedCELCCELCUITY INC+31.4%$38.7M
- AddedIRONDISC MEDICINE INC+16.6%$38.4M
- AddedCADLCANDEL THERAPEUTICS INC+14.1%$34.0M
- AddedXFORX4 PHARMACEUTICALS INC+8.0%$32.6M
- AddedDYNDYNE THERAPEUTICS INC+9.4%$23.5M
- NewTRVITREVI THERAPEUTICS INC—$19.6M
- ReducedALMSALUMIS INC−9.0%$82.0M
- ReducedABVXABIVAX SA−4.4%$69.1M
- ReducedJAZZJAZZ PHARMACEUTICALS PLC−1.2%$38.8M
- ReducedMNPRMONOPAR THERAPEUTICS INC−9.7%$28.9M
- ReducedIVVDINVIVYD INC−23.4%$7.3M
- ReducedOVIDOVID THERAPEUTICS INC−84.1%$1.8M
- SoldCOGTCOGENT BIOSCIENCES INC−100%—
Reading Saturn V Capital Management LP’s 13F portfolio
Saturn V Capital Management LP’s $697.5M 13F book is spread across 23 reported positions and is highly concentrated — its ten largest positions alone are 76% of the portfolio. A book this concentrated means a small group of names drives most of its performance. Its five largest positions are AMLX, ALMS, ABVX, PCVX and IMMX, led by AMYLYX PHARMACEUTICALS INC (AMLX) at 12% of the portfolio. The heaviest sector exposure is Healthcare (100%).
What Saturn V Capital Management LP changed last quarter
Between 2026-03-31 and Q2 2026, Saturn V Capital Management LP was a net buyer: it opened 3 new positions and added to 13 more, while trimming 6 and closing 1 outright. Against a 23-name book, that is high turnover, pointing to an active reshuffle of the book. Its largest new or increased position was AMYLYX PHARMACEUTICALS INC (AMLX), and its biggest reduction was ALUMIS INC (ALMS).
What a 13F does and doesn’t reveal
A 13F captures only Saturn V Capital Management LP’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names Saturn V Capital Management LP is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.
Frequently asked questions
What is an SEC 13F filing?
A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. Saturn V Capital Management LP's profile on this page is built directly from those filings.
How current is the 13F data on Saturn V Capital Management LP's page?
It reflects Saturn V Capital Management LP's most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When Saturn V Capital Management LP files its next quarterly report, this page refreshes automatically.
Can I see Saturn V Capital Management LP's complete list of holdings?
This page highlights Saturn V Capital Management LP's largest positions rather than all 23 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under Saturn V Capital Management LP's filings.
Does a 13F show everything Saturn V Capital Management LP owns?
No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of Saturn V Capital Management LP's book rather than its full strategy or total assets.
Is 13F data investment advice?
No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why Saturn V Capital Management LP made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.
Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.

